Adaptive Biotechnologies Corporation (ADPT)

NASDAQ • Healthcare

$28.35

+$0.98 (+3.6%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$27.59

Day Range$27.31 - $28.41

Avg. Volume (3M)2.5M

Market Cap$4.5B

52 Week Range

$12$29.96

Next EarningsIn 31 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$71.5M100%

Gross Profitminus cost of goods$50.9M71%

In plain terms: out of every $100 in revenue, Adaptive Biotechnologies Corporation currently loses $56.

Fundamentals & Financials

Revenue (TTM)

$308M

Net Income (TTM)

-$63.8M

EPS (TTM)

-$0.41

ROA (TTM)

-9.97%

Current Ratio

4.79

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+29.2%Q3 2025-$0.17

+133.3%Q4 2025$0.06

+52.6%Q1 2026-$0.09

+18.8%Q2 2026-$0.13

-87.1%Q3 2026-$0.25

Nov 4

in 31 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -87.1%

Adaptive Biotechnologies missed on EPS but beat on revenue in the second fiscal quarter of 2026, reported on July 29; revenue rose about 22% to about $71.6 million from $58.9 million a year ago, while EPS came in at -$0.25 versus the -$0.13 estimate, a miss of about -87.1%. Gross profit reached about $51.0 million, with gross margin near 71% and operating margin around -22%, and net income fell to a loss of about $39.8 million from a $25.6 million loss a year ago, about -55.3%. Operating cash flow was negative about $6.4 million, and the company repurchased about $25.0 million of stock. Consensus for the next period calls for EPS of -$0.10 on revenue of $71.6 million.

View full earnings history

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation is a NASDAQ-listed biotechnology company focused on immune medicine. It develops clinical products and services used to diagnose, monitor, and inform treatment across cancer, autoimmune disorders, and infectious diseases, and it generated $277.0 million of revenue in FY2025.

Name

Adaptive Biotechnologies Corporation

CEO

Chad Robins

Website

www.adaptivebiotech.com

Industry

Healthcare

Year Founded

2009

Employees

624

Today's Snapshot

AI-generated

ADPT closed 3.6% higher at 28.35, while its sector was flat. Volume was about half of its usual level.

Trading Volume

Below 10d avg (2.6M)

1.4M

vs S&P 500 Today

Outperforming Market

+2.80%

Updated: October 2, 2026 at 20:15 UTC

Technical Indicators

5 Buy3 Neutral0 Sell

ADPT shows a bullish intermediate structure as price sits above key medium- and long-term averages while short-term averages are essentially flat, and on-balance volume is positive, supporting the move. Momentum readings are generally neutral-to-positive with MACD near positive territory, ADX signals only modest trend strength, and ATR denotes moderate volatility; the classic pivot is below the market, which supports the current price footing. Technical takeaway: Strong Buy.

All signals